Oral contraceptive approved for acne vulgaris
Birth control pill Yaz, containing a combination of drospirenone 3 mg and ethinyl estradiol 20 mcg, has received approval for yet another indicationthe treatment of acne vulgaris in women who desire an oral contraceptive for birth control. According to manufacturer Berlex, this marks the first time an oral contraceptive has received approval for three indications. Yaz was previously indicated as an oral contraceptive and as a treatment for the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD). The drospirenone component has mineralocorticoid and antiandrogenic properties, the latter of which blocks male sex hormones that can cause acne.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
